Home > PE Ratio > LINCOLN PHARMACEUTICALS

LINCOLN PHARMACEUTICALS
PE (Price/Earnings) Ratio

The Current P/E Ratio of LINCOLN PHARMACEUTICALS is 13.63.

Share Price ₹594.7Apr 29,2024
Market Cap ₹1,189.4 Cr
Earnings-TTM₹87.3 CrTTM-Consolidated Results
Price/Earnings13.63xCalculated as Market Cap/Earnings
Explore Stock Analytics
COMMUNITY POLL
for LINCOLN PHARMACEUTICALS
Please provide your vote to see the results
LINCOLN PHARMACEUTICALS is part of below Screeners ↓
Top Small Cap Stocks with Best Fundamentals
Best Quarterly Growth Small Cap Stocks

Definition & Calculation of PE (Price/Earnings) ratio of LINCOLN PHARMACEUTICALS

Price-to-Earnings ratio, P/E Multiple, or P/E Ratio is an important valuation multiple that is defined as:

P/E = Market Capitalization / Net Income

or, using per-share numbers:

P/E = Stock Price / Earnings Per Share (EPS)

Applying the above formula, P/E ratio of LINCOLN PHARMACEUTICALS is calculated as :

Current Market Cap [ ₹1,189.4 Cr] as on Apr 29,2024

(/) Earnings [ ₹87.3 Cr] based on TTM-Consolidated Results

(=) P/E Ratio [ 13.63x ]

P/E Ratio indicates the multiple of earnings investors are willing to pay to own one share of the company.

Thus, for LINCOLN PHARMACEUTICALS , the investors are currently willing to pay 13.63 times earnings to own 1 share of the company.

PE Multiples are the most widely used valuation multiple in practice.

Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.

In such cases, you may consider using Price to Book ratio or Price to Sales ratio of LINCOLN PHARMACEUTICALS !

P/E ratios, also, would not adjust for differences in the capital structure between companies.

The chart below summarizes the trend in P/E Ratio of LINCOLN PHARMACEUTICALS over the last five years.

Historical PE (Price/Earnings) ratio chart of LINCOLN PHARMACEUTICALS


PE Ratio Performance Analysis for LINCOLN PHARMACEUTICALS

- LINCOLN PHARMACEUTICALS 's latest p/e ratio is 13.63x.

- LINCOLN PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2023 to Mar2019 averaged 7.89x.

- LINCOLN PHARMACEUTICALS 's operated at median p/e ratio of 8.73x from fiscal years ending March 2018 to 2022.

- Looking back at the last 5 fiscal years, LINCOLN PHARMACEUTICALS 's p/e ratio peaked in Mar2023 at 9.31x.

- LINCOLN PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2020 of 5.2x.


How does LINCOLN PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?

Peer Comparison (Pharmaceuticals & Drugs Industry)Earnings-TTM (Cr)PE RatioMarket Cap
LINCOLN PHARMACEUTICALS 87.2713.631,189.4
SUN PHARMACEUTICAL INDUSTRIES LTD8,998.6340.58365,167.0
CIPLA LTD3,744.0330.35113,645.0
DR REDDYS LABORATORIES LTD5,209.4020.15104,987.0
ZYDUS LIFESCIENCES LTD2,954.2032.8296,950.6
DIVIS LABORATORIES LTD1,382.9776.57105,890.0
MANKIND PHARMA LTD1,743.3054.7895,492.3
TORRENT PHARMACEUTICALS LTD1,494.0060.9090,980.9
LUPIN LTD1,809.7441.2474,631.4
AUROBINDO PHARMA LTD2,777.8924.2967,488.4
ABBOTT INDIA LTD1,145.5848.7455,838.1

Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs LINCOLN PHARMACEUTICALS 's P/E Ratio

Top 10 Industry PeersPE Ratio
Min industry PE 13.63x
Max industry PE 76.57x
Median industry PE 40.58x
Average industry PE 40.37x



You may also like the below Video Courses